RxDoctor Payments Data

Brenda Wallace, PA

Physician Assistant · Rockwall, TXNPI 1104130426

Payments from drug & device makers

$6,332in general payments, 2019–2025

Across 331 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$814
  • Lilly USA, LLC$505
  • Astellas Pharma US Inc$447
  • Abbott$424
  • GSK$411
  • Novo Nordisk$373
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$6,23298%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,332 in reported general payments places this provider in the 90th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$58,525
Medicare patients
212
Services billed
847

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$72,785
MounjaroTirzepatide24$49,583
JardianceEmpagliflozin29$41,544
EliquisApixaban26$35,310
FarxigaDapagliflozin Propanediol33$29,159
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$28,503
XareltoRivaroxaban17$14,866
LinzessLinaclotide11$13,828
MyrbetriqMirabegron13$10,015
Gabapentin152$3,537
Levothyroxine Sodium321$2,779
SynthroidLevothyroxine Sodium32$2,477
Atorvastatin Calcium279$2,123
Duloxetine Hcl51$1,769
Metoprolol Succinate134$1,731

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$373$72,78573 claims
Lilly USA, LLCMounjaro$505$49,58324 claims
Boehringer IngelheimJardiance$46$41,54429 claims
PfizerEliquis$289$35,31026 claims
AstraZenecaFarxiga$298$29,15933 claims
GSKTrelegy Ellipta$411$28,50329 claims
AbbVieLinzess, Synthroid$814$16,30543 claims
Johnson & JohnsonXarelto$53$14,86617 claims
Astellas Pharma US IncMyrbetriq$447$10,01513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →